Nebenwirkungen · Inhixa
Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 45–46
HOS-136985 · Präparat HOS-097950
45 Thrombocytopenia and thrombocytosis (see section 4.4 monitoring of platelet counts) System Prophylaxis in Prophylaxis Treatment in Extended Treatment in Treatment in organ surgical in medical patients with treatment of patients with patients with class patients patients DVT with or DVT and PE unstable acute STEMI without PE in patients angina and with active non-Q-wave cancer MI Blood Very common: Uncommon Very common: Unknown: Uncommon: Common: and Thrombocyto : Thrombocyto Thrombocyt Thrombo- Thrombocyto lympha sisβ Thrombo- sisβ openia cytopenia sisβ tic cytopenia Thrombo- system Common: Common: cytopenia disorde Thrombo- Thrombo- Very rare: rs cytopenia cytopenia Immuno- allergic thrombo- cytopenia β : Platelet increased >400 G/L
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-16T09:35:00Z · SHA-256 bbb8302fcca3a170cc14307df6fa307c1fd979d2c3ae4a14f42ba825950d23d7 · Passage 869dc03575b8903f6d92c3f430e28fc77059517e70c15fb425ed6807c2b8481c · Zeichen 7334–9026 im Abschnitt